1

Phase 3 Starts for mRNA‑4157 in Melanoma & NSCLC (Mid‑2023)

 News Discuss 
Following promising Phase 2 outcomes, pivotal Phase 3 trials began in mid‑2023 for adjuvant melanoma and NSCLC indications . https://www.datamintelligence.com/research-report/mrna-vaccines-market---pipeline-insights

Comments

    No HTML

    HTML is disabled


    Report Page

Who Upvoted this Story

Search

Published News